Nasus Pharma initiated with a Buy at Laidlaw

Laidlaw analyst Yale Jen initiated coverage of Nasus Pharma (NSRX) with a Buy rating and $22 price target The firm says Nasus is a mid-clinical stage biotech company focusing on the development of NS-002, a “well differentiated” powder-based intranasal anaphylaxis treatment. The “compelling” NS-002 in anaphylaxis Phase II study outcomes bode well for a successful Phase III study and potential approval as the first powder-based intranasal anaphylaxis therapy, the analyst tells investors in a research note.